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Abstract 
Review on EP300, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: P300, KAT3B 
HGNC (Hugo): EP300 
Location: 22q13.2 
DNA/RNA 
Description 
p300 was first discovered on the basis of its 
interaction with the adenoviral protein E1A and 
EP300 locus was subsequently mapped to the long 
arm of chromosome 22, spanning about 88 kb 
(Whyte et al., 1989; Eckner et al., 1994). 
Transcription 
EP300 has only one splice variant derived from the 
splicing of its 31 exons with an mRNA of 9585 bp 
which includes 1219 and 1121 bp of 5'UTR and 
3'UTR, respectively. 
Pseudogene 
No pseudogenes are known. 
Protein 
Description 
p300 is a large size protein of about 264 kDa 
belonging to the KAT3 (lysine or K-
acetyltransferase) family (Valor et al., 2013). 
p300 shares a modular organization consisting in 
several conserved domains including a central 
chromatin association and modification region 
which includes the bromodomain/PHD finger 
module and the KAT11 domain (Rack et al., 2014) 
which is flanked by four transactivation domains 
(TADs): i) the CH1 that encompasses the TAZ1 
domain, ii) the KIX domain, iii) another CH3 
containing the TAZ2 domain and a ZZ domain, and 
iv) the IBiD (Bedford et al., 2012; Wang et al.,
2013). 
Schematic representation of EP300 gene. Black boxes represent exons and gray ones 5' and 3' UTRs. Thin black lines 
represent introns. (Modified from Zimmerman et al., 2007). 
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Schematic structure of p300 protein including its functional and structural domains and their localization. NLS (nuclear 
localization signal), CH1 (cysteine/histidine-rich region 1, also known as transcriptional-adaptor zinc-finger domain 1 or TAZ1), 
KIX (kinase inducible domain of CREB interacting domain), BROMO (bromodomain), PHD (plant homeodomain finger), KAT11 
(lysine acetyltransferase domain), ZZ (ZZ-type zinc finger domain), TAZ2 (transcriptional-adaptor zinc-finger domain 2; ZZ and 
TAZ2 together are sometimes referred to as CH3 or cysteine/histidine-rich region 3), and IBiD (IRF3-binding domain). Aminoacid 
positions are from UniGene NP_001420.2. 
 
The Bromodomain mediates p300 binding to 
acetylated histones, nucleosomes and transcriptional 
factors and could therefore play a role in tethering 
p300 to specific chromosomal sites (Kalkhoven et 
al., 2004; Rack et al., 2014) moreover, the associated 
PHD finger is an integral part of the enzymatic core 
of the protein influencing its ability to recognize and 
acetylate both itself as well as histones and non-
histone substrates (Kalkhoven et al., 2004; Wang et 
al., 2013; Rack et al., 2014). The KAT11 catalytic 
domain can acetylate p300 itself and a variety of 
histonic and non-histonic proteins and the CH rich 
regions are able to bind zinc and are involved in 
protein-protein interaction (Valor et al., 2013; Wang 
et al., 2013). 
p300 has also multiple specific interaction domains 
for different transcriptional factors such as the KIX 
domain that mediates CREB-p300 interaction and 
CREB phosphorylation at serine 133 residue but also 
for the Retinoic Acid Receptor-related orphan 
receptor A (RORA) and for ALX1 at the N-term end 
of the protein and for Interferons at C-term end. 
Expression 
p300 is ubiquitously expressed in human tissues 
(Kalkhoven et al., 2004; Valor et al., 2013). p300 is 
highly evolutionary conserved and present in many 
multicellular organisms including flies, worms and 
plants but not in lower eukaryotes such as yeasts 
(Kalkhoven et al., 2004). 
Localisation 
p300 is a nuclear protein which resides in a specific 
nuclear structure called nuclear body (Chan and La 
Thangue, 2001). 
Function 
p300 is a transcriptional coactivator with intrinsic 
lysine acetyltransferase activity able to regulate 
transcription and gene expression in different ways. 
1) Acetylation of histones tails: p300 can enable 
transcription through the catalytic activity of its 
KAT domain which is able to acetylate promoter 
nucleosomal histones resulting in chromatin 
remodelling and relaxation and in increased 
accessibility of the DNA to other essential regulators 
(Kalhoven et al., 2004; Wang et al., 2013).  
Thanks to its ability in modifying chromatin 
structure by histone acetylation, p300 can be defined 
as "writer" of the epigenetic code (Berdasco et al., 
2013). 
2) Acetylation of other target proteins: p300 can also 
acetylate other kinds of proteins, such as 
transcriptional factors, modulating their activity 
positively or negatively, or coactivators. 
Acetylation of non-histone substrates can result in 
either positive or negative effects on transcription by 
affecting protein-protein interactions (activator of 
thyroid and retinoid receptors ACTR), protein-DNA 
interactions (the high mobility group protein 
HMGI), nuclear retention (the hepatocyte nuclear 
factor HNF4) or protein half-life (E2F). 
For example some acetylated p300 targets regulate 
the expression of histone methyltransferase leading 
to chromatin condensation and gene silencing. 
3) RNA Polymerase II stabilization: p300 functions 
as a "bridge" linking the DNA-bound transcription 
factors (activators) to the basal transcription 
machinery through direct interaction with TFIID, 
including TATA-binding protein (TBP) and 13 TBP-
associated factors (TAFs) and TFIIB promoting the 
pre-initiation complex (PIC) assembly (Wang et al., 
2013). 
p300 has also some more indirect chromatin-related 
roles: 
4) DNA replication and repair: p300 interacts with 
various replication and repair proteins, including 
proliferating cell nuclear antigen (PCNA), the Recq4 
helicase, Flap endonuclease 1 (Fen1), DNA 
polymerase b and thymine DNA glycosylase, with 
the latter three also serving as acetylation substrates. 
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Comparison of p300 and CBP amino acidic sequences. The blue regions indicate the areas of highest homology with the 
percentage of amino acid identity specified in between. Position of the corresponding domains are taken from UniGene 
(NP_001420.2 for EP300 and NP_004371.2 for CREBBP). (Modified from Chan and La Thangue, 2001). 
 
5) Cell cycle regulation: p300 associates with the 
complex formed between cyclin E and cyclin-
dependent kinase 2 (cdk2) regulating proper 
progression of the cell cycle. 
6) p53 activity regulation: p300 is involved in p53 
degradation, which depends on the murine double 
minute 2 protein (MDM2). Degradation and 
ubiquitination of p53 is dependent on MDM2, and a 
ternary complex between these two proteins and 
p300 regulates the turnover of p53 itself in cycling 
cells. Furthermore, the CH-1 region of p300 displays 
polyubiquitin ligase activity towards p53, and could 
therefore play a key role in controlling p53 levels. 
7) Nuclear import: p300 can acetylate two proteins 
involved in regulating nuclear import, the importin-
α1 isoform Rch1 and importin-α7, and could 
therefore play a role in this process. 
Because of its ability of interacting with more than 
400 partner proteins, p300 can be considered a "hub" 
(Bedford et al., 2014). Its interactome includes pro-
proliferative proteins and oncoproteins: c-Myc, c-
Myb, CREB, c-Jun and c-Fos; transforming viral 
proteins: E1A, and E6; as well as tumor suppressors 
and pro-apoptotic proteins: Forkhead box class O 
(FoxO) transcription factors FoxO1, FoxO3a, and 
FoxO4, signal transducers and activators of 
transcription (STAT) 1 and STAT 2, Hypoxia-
inducible factor 1α (HIF-1α), breast cancer 1 
(BRCA1), SMA/MAD homology (Smad) proteins, 
the Runt-related transcription factor (RUNX), E2 
Transcription Factor (E2F), and E-proteins (Wang et 
al., 2013). 
Homology 
p300 is highly homologous to the cyclic AMP 
response element-binding (CREB) binding protein 
(CBP) with 63% identity and 75% similarity at 
amino-acid level (Narayanan et al., 2004; Wang et 
al., 20113). CREBBP/CBP locus was mapped on 
16p13.3, a region of extensive homology to the one 
on chromosome 22 where EP300/p300 resides (Chan 
and La Thangue, 2001; Gervasini, 2010). 
Mutations 
Germinal 
Rubinstein-Taybi Syndrome (RSTS; OMIM 
#180849, #613684). 
Somatic 
Cancers derived from almost all tissues and organs, 
such as those of hematopoietic and lymphoid organs, 
cancers of eye, skin, bones, thyroid, salivary and 
adrenal glands, central nervous system (CNS) 
including meninges, and nervous system (NS) 
including automatic ganglia, esophagus, upper 
aerodigestive tract, lung and pleura, stomach, liver, 
pancreas, biliary tract, large and small intestine, 
kidney, urinary tract and breast, endometrium, 
cervix, ovary and prostate. 
Epigenetics 
The identification of mutations in epigenetic genes, 
classified as writers, readers and erasers based on 
their function (Berdasco and Esteller, 2013), 
represents a link between the cancer epigenome and 
genetic alterations acting as "driver" or "passenger" 
mutations in cancer development.  
Actually, many genetic alterations in cancer 
epigenetic regulators cause cancer-associated 
phenotype via epigenetic dysfunction (Roy et al., 
2014). 
Implicated in 
Rubinstein-taybi syndrome (RSTS; 
OMIM #180849, #613684) 
Note 
Germinal mutations leading to loss of 
function/haploinsufficiency. 
Disease 
Rubinstein-Taybi syndrome is a rare (1:125000 live 
birth) autosomal dominant neurodevelopmental 
disorder.  
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EP300 germline mutations in Rubinstein-Taybi patients (2014 update). A) Point mutations, B) intragenic deletions and C) 
schematic of the gene with type and localization of all 26 mutations reported so far. (Modified from Negri et al., 2014). 
 
 
It is characterized by postnatal growth retardation, 
intellectual disability (ID), skeletal anomalies (broad 
and/or duplicated distal phalanges of thumbs and 
halluces are a landmark sign) and distinctive facial 
dysmorphisms including down-slanting palpebral 
fissures, broad nasal bridge, beaked nose and 
micrognathia (Hennekam, 2006). 
Prognosis 
All EP300-mutated RSTS patients described in 
literature are alive (Roelfsema et al., 2005; Bartholdi 
et al., 2007; Zimmermann et al., 2007; Foley et al., 
2009; Bartsh et al., 2010; Tsai et al., 2011; Negri et 
al., 2014). 
Hybrid/Mutated gene 
The identification of EP300 as the second RSTS 
causative gene in 2005 (Roelfsema et al., 2005) 
disclosed the heterogeneous nature of the syndrome. 
EP300 heterozygous point mutations and intragenic 
deletions have been detected in about 8% of RSTS 
CREBBP-negative cases (Negri et al., 2014). 
Fourteen patients are clinically and genetically 
described (Roelfsema et al., 2005; Bartholdi et al., 
2007; Zimmermann et al., 2007; Foley et al., 2009; 
Bartsh et al., 2010; Tsai et al., 2011; Negri et al., 
2014), while 12 additional alterations are reported in 
the LOVD database . 
Oncogenesis 
RSTS patients (estimated incidence 5%) have an 
increased predisposition to malignancies like 
leukemia, neuroblastoma, meningioma and 
pilomatrixoma, developed either in the first years of 
life or in mid-adulthood (30-40 years) (Siraganin et 
al., 1989; van de Kar, 2014). Glaucomas and keloids 
are reported too; in particular, EP300-mutated RSTS 
patients show a slight increase in developing skin 
anomalies such as keloids (Van Genderen et al., 
2000; van de Kar, 2014; Negri et al., 2014). 
Various cancers 
Note 
All data are taken from COSMIC database 
(Catalogue of Somatic Mutations In Cancer) 
(Release v70 August 2014). 
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EP300 somatic point mutations load. A) Pie chart of the main kinds of point mutations and relative numbers, B) bar chart of 
the distribution of the mutations within the gene domains and C) recurrent mutations and localization. Data are reworked from 
COSMIC database. 
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Disease 
EP300 point mutations, copy number variations 
(CNVs) but also gene expression profile alterations 
have been detected in almost all human cancers 
independently of the embryonic origin. Out of 
>14.000 tumor samples tested, those derived from 
hematopoietic and lymphoid organs, lung, central 
nervous system (CNS), breast, intestine and ovary 
show the highest prevalence of EP300 mutations. 
Hybrid/Mutated gene 
The majority of EP300 point mutations detected in 
tumoral samples are heterozygous (Aumann et al., 
2014). 
With about ~400 unique somatic alterations 
reported, point mutations appear to be the most 
represented kind of EP300,mutations: in particular, 
missense mutations account for >60% of all 
mutations, followed by synonymous (~13%) and 
nonsense (~11%) mutations. In detail, transitions 
justify about 70% of all substitutions. Out of frame 
insertion/deletions (ins/del) represent together 38% 
and in frame ins/del about 4%. 
Mutations are widespread across the gene with a 
great concentration in the large KAT11 domain, 
which clusters about 26% of all alterations. Few 
recurrent mutations are reported: the most frequently 
mutated amino acid residue is the aspartic acid at 
position 1339 in the KAT11 domain which is 
replaced by either asparagine (eight samples) or 
tyrosine (four samples). 
CNVs are described too. In particular, losses are 
reported in 31 samples including breast, 
endometrium, ovary, large intestine and lung cancer, 
while gains seem to be rarer being described in 11 
samples including breast, hematopoietic and 
lymphoid, and lung cancer. 
Alterations in EP300 gene expression are recorded 
too: in particular over expression was described in 
94 samples, while under expression in 104 samples, 
both in cancers derived from breast, endometrium, 
ovary, CNV, haematopoietic and lymphoid organs, 
kidney, large intestine and lung. 
Oncogenesis 
The oncogenic mechanism by which EP300 
mutations act is not yet clear, but as the most 
frequently mutated region is the lysine 
acetyltransferase domain, which catalyzes 
acetylation of histones and other essential proteins, 
aberrant acetyltransferase activity may be a key 
feature. In vitro studies demonstrated reduced 
H3K18 acetylation, as well as decreased ability to 
acetylate p53 and BCL6, in p300- mutated cells 
(Peifer et al., 2012). Because of p300 multiple 
functions and diverse interactions, many intertwisted 
mechanisms could play a role in the different 
mutations' effects. 
t(11;22)(q23;q13) resulting in MLL1-
EP300 fusion gene 
Note 
Somatic mutations. 
Disease 
Therapy-related leukemias and myeloid neoplasms. 
Cytogenetics 
Ida et al., described the first patient presenting the 
karyotype 48,XY,+8,+8,(11;22)(q23;q13); the same 
group (Ohnishi et al.) described a second patient 
with 46,XX,t(1;22;11)(q44;q13;q23), 
t(10;17)(q22,q21), while a third patient, with 
46;XY,t(11;22)(q23;q13)[15]/47,idem,+8[2], was 
reported by Duhoux et al. 
Hybrid/Mutated gene 
Rearrangements of the mixed lineage leukemia 
(MLL1 or KMT2A; gene ID: 4297) locus are 
frequently encountered in acute leukemias and at 
least 104 different chromosomal rearrangements 
involving MLL1 itself with more than 64 
translocation partner genes have been described 
(Meyer et al., 2009) while rearrangements of EP300 
gene locus seem to be rare events. 
Only three cases of MLL1-EP300 fusion genes have 
been described, all in therapy-related leukemia 
patients following chemoterapy with topoisomerase 
II inhibitors. The first patient was initially diagnosed 
as having non-Hodgkin lymphoma and, after 
conventional chemotherapy, he developed 
secondary AML which was cytogenetically 
characterized as t(11;22)(q23;q13) producing a 
chimeric MLL1-EP300 gene in which the exon 9 of 
MLL1 was juxtaposed to EP300 exon 15 (Ida et al., 
1997). The second case is a girl who developed AML 
after chemotherapy for neuroblastoma. She 
presented a complex karyotype 
46,XX,t(1;22;11)(q44;q13;q23),t(10;17)(q22,q21) 
with the fusion of MLL1 exon 8 to EP300 exon 15 
and also a less expressed clone in which exon 7 of 
MLL1 is fused with exon 15 of EP300, which was 
considered to be generated by alternative splicing 
(Ohnishi et al., 2008). The third patient presented 
AML with myelodysplasia-related changes evolving 
after chemotherapy in acute myelomonocytic 
leukaemia (AMML). Leukemic cells were 
cytologically characterised as 
46;XY,t(11;22)(q23;q13)[15]/47,idem,+8[2] 
including the fusion of exon 10, or exon 11 resulting 
from alternative splicing, of MLL1 with exon 13 of 
EP300 (Duhoux et al., 2011). 
All chimeric proteins retain almost the same part of 
both MLL1, including the AT-hook, the DNA 
methyltransferase and the transcriptional repression 
domains and p300, i.e. the bromodomain, the 
catalytic KAT and TADs 
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t(11;22)(q23;q13) leads to fusion of MLL1 gene to EP300. A) Schematic representation of MLL1, p300 and the predicted 
MLL1-p300 fusion proteins of all reported cases (Ida et al., 1997; Ohnishi et al. 2008; Duhoux et al., 2011). B) Nucleotide 
sequences of the hybrid junctions of the chimeric MLL1-EP300 genes and relative references. Breakpoints are indicated by 
arrows; AT: AT hooks, NLS: nuclear localization signals, CxxC: motif recognizing unmethylated CpG dinucleotides, PHD: plant 
homeodomain fingers, TAD: transactivation domain, SET: histone methyltransferase active sites; CH: cystidine/histidine-rich; 
KIX: kinase inhibitory domain, Bromo: bromodomain, KAT: Lysine acetyltransferase domain. (Modified from Duhoux et al., 2011). 
 
Oncogenesis 
The fusion of MLL1 with the lysine-
acetyltransferase p300 supposedly leads to 
hyperacetylation of chromatin which contributes to 
increase the transcriptional output conferring a 
significant oncogenic advantage to the cells. 
Furthermore, nuclear factors, such as p300, have 
transcriptional activity and their function might be 
deregulated by the fusion with MLL1 (Ohnishi et al., 
2008; Duhoux et al., 2011). 
The translocation t(11;22)(q23;q13) involving 
MLL1-EP300 is characteristic of therapy related 
leukemias where it is likely driven by topoisomerase 
II inhibitors, rather than of de novo leukaemias. 
t(8;22)(p11;q13) resulting in MOZ-
EP300 fusion gene 
Note 
Somatic mutations. 
Disease 
de novo, progression or therapy-related AML. 
 
 
Cytogenetics 
The t(8;22)(p11;q13) is a rare translocation found in 
acute myeloid leukaemia (AML) described in only 
three patients (Lai et al., 1992; Soenen et al., 1996; 
Chaffanet et al., 2000; Kitabayashi et al., 2000; 
Tasaka et al., 2002). The first patient was diagnosed 
as having a de novo AML with karyotype 47, 
XY,+8,t(8;22)(p11;q13), while the second patient 
suffered from a chronic myelomonocytic leukaemia 
(CMML) which evolved in AML with the abnormal 
karyotype: 
46,XY,t(8;22)(p11;q13)/idem,+der(8)t(8;22)(p11;q
13)del(17)(p11) (Lai et al., 1992; Soenen et al., 
1996; Chaffanet et al., 2000). The third case is a man 
with primary macroglobulinemia who developed a 
secondary AML during chemotherapy, with the 
karyotype: 47, XY, 
t(8;22)(p11.2;q13.1),+der(8)t(8;22)(22qter→22q13.
1::8p11.2→8q13::8q22→8qter),add(19)(p13.3) 
(Kitabayashi et al., 2001; Tasaka et al., 2002). 
Hybrid/Mutated gene 
Monocytic leukemia zinc finger gene (MOZ, Gene  
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Schematic representation of the p300, MOZ, MOZ-p300 and p300-MOZ proteins. A) p300, MOZ, p300-MOZ and MOZ-p300 
diagram of the first case and B) p300, MOZ, p300-MOZ and MOZ-p300 diagram of the third one. Red arrows indicate the 
breakpoints of the translocations and nucleotide sequences of WT and hybrid junctions are reported. The functional domains of 
MOZ and p300 as well as those of fusion proteins are indicated above and beneath the diagrams. NID: nuclear receptor 
interaction domain, CH1-3: cysteine/histidine-rich domain, CID: CREB-interaction domain, B: bromodomain, KAT: lysine 
acetyltransferase domain, Q: glutamine-rich region, PH: PHD class zinc finger, MYST: MOZ, YB1, SAS, TIP homology domain, 
S: serine-rich region, PQ: proline/glutamine region, M: methionine-rich region. (Modified from Kitabayashi et al., 2001). 
 
 
ID: 7994) codifies for a Myst (MOZ, Ybf2 (Sas3), 
Sas2, Tip60)-type lysine acetyltransferase (KAT) 
also named KAT6A (lysine acetyltransferase 6A). 
The gene underlies chromosomal translocation with 
different partners, generating fusion genes, such as 
MOZ-TIF2, MOZ-CBP and MOZ-EP300 in acute 
myeloid leukemia (AML). All MOZ fusion partner 
genes are involved in histone modification and 
transcriptional regulation (Katsumoto et al., 2008). 
To date, only three cases of t(8;22)(p11;q13) 
involving MOZ and EP300 have been reported and 
investigated at DNA and RNA levels in two of them 
(Lai et al., 1992; Soenen et al., 1996; Chaffanet et 
al., 2000; Kitabayashi et al., 2001; Tasaka et al., 
2002). 
In Chaffanet et al., and in Kitabayashi et al., MOZ-
EP300 fusion genes result from the hybrid junction 
between exon 16 and exon 15 of MOZ with exons 2 
and 3 of EP300, respectively. 
In both cases, the MOZ breakpoints are located in or 
around its acidic domain resulting in the retention of 
its N-terminal region and the replacement of the C-
terminal end with the p300 fusion partner. The N-
terminal region of MOZ contains a H15 (histone 
H1/H5) domain related to nuclear localization, a 
PHD (plant homeobox-like domain) zinc finger 
involved in binding to methylated histones, a basic 
domain and a Myst-type KAT domain. The KAT 
domain contains C2HC zinc finger and helix-turn-
helix motifs that bind to nucleosomes and DNA. 
Because of the early truncation of EP300 , almost all 
its functional domains are conserved, including the 
KAT, the bromodomain and the CH1-3, resulting in 
a fusion protein with both MOZ and p300 KAT 
domains. 
In the reciprocal fusion genes, EP300-MOZ, exon 1 
or 2 of EP300 are juxtaposed to exons 17 and 16 of 
MOZ, respectively. In both cases, the N-terminal 
region including only the nuclear receptor 
interaction domain (NID) of p300 and the C-terminal 
of MOZ encompassing its serine, proline-
glutammine and methionine-rich regions are 
conserved (Chaffanet et al., 2000; Kitabayashi et al., 
2001). 
Oncogenesis 
The conservation of MOZ and p300 KAT catalytic 
domains in the hybrid proteins MOZ-p300 may 
result in abnormal acetylation of histonic and non 
histonic proteins with a consequent alteration in gene 
expression regulation, leading to leukaemogenesis; 
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furthermore, MOZ-p300 fusion proteins retain the 
domains required for the interaction with AML1 thus 
affecting AML1-dependent transcription whose 
deregulation may be implicated in leukaemogenesis 
too (Kitabayashi et al., 2001). 
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